Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 3Gynecologic 1Breast 1

Conditions

Ovarian Neoplasms 45Uterine Cervical Neoplasms 22Fallopian Tube Neoplasms 20Carcinoma, Ovarian Epithelial 15Neoplasms 8Endometrial Neoplasms 8Lung Neoplasms 7Breast Neoplasms 5Stomach Neoplasms 4Recurrence 4Pancreatic Neoplasms 4Neoplasm Metastasis 4Melanoma 4Head and Neck Neoplasms 4Gestational Trophoblastic Disease 4Vulvar Neoplasms 3Peritoneal Neoplasms 3Kidney Neoplasms 3Esophageal Neoplasms 3Colorectal Neoplasms 3Uterine Neoplasms 2Sarcoma 2Lymphoma, Non-Hodgkin 2Liver Neoplasms 2Laryngeal Neoplasms 2Hydatidiform Mole 2Gynecologic Cancer 2Glioblastoma 2Colonic Neoplasms 2Cholangiocarcinoma 2

Interventions

Cisplatin 3Etoposide 2Amifostine 2sargramostim 1Pyridoxine 1Methotrexate 1Erythropoietin 1Epoetin Alfa 1Drug Therapy 1Cyclophosphamide 1Brachytherapy 1Bleomycin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Drug-Related Side Effects and Adverse Reactions × Drug Therapy × Gynecologic × Clear all
NCT04635956 2020-11-19

Camrelizumab Combined With Chemotherapy for Recurrent or Advanced Cervical Neuroendocrine Carcinomas

Peking Union Medical College Hospital

Phase 2 Unknown
20 enrolled
Gynecologic

Uterine Cervical Neoplasms, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡